ImmunityBio Gains Crucial European Market Access for Bladder Cancer Therapy
21.02.2026 - 10:29:04 | boerse-global.de
ImmunityBio has achieved a significant regulatory milestone in Europe, securing conditional marketing authorization from the European Commission for its therapy, ANKTIVA. This approval opens a substantial new market for the company and is expected to accelerate its commercial rollout. The key question now is how swiftly the biopharmaceutical firm can translate this authorization into tangible sales and distribution.
The European Commission granted conditional approval for ANKTIVA (nogapendekin alfa inbakicept) this week. It is authorized for use in combination with Bacillus Calmette-Guérin (BCG) for adult patients diagnosed with BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) of the carcinoma in situ (CIS) type, with or without accompanying papillary tumors. Read more...
